KRAS and non-small cell lung carcinoma: The key mutation in PDAC is KRAS, which is notoriously resistant to drugs; however, KRAS inhibitors are indeed emerging, with the recent FDA approvals in non-small cell lung cancers of two KRAS G12C-targeting drugs, sotorasib [26] and adagrasib [27].